bocunebart

News

Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

News

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.